Abstract
The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Current Pharmaceutical Design
Title: Humanized SCID Mice Models of SLE
Volume: 17 Issue: 13
Author(s): Nikola Kerekov, Nikolina Mihaylova, Jozsef Prechl and Andrey Tchorbanov
Affiliation:
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Abstract: The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Export Options
About this article
Cite this article as:
Kerekov Nikola, Mihaylova Nikolina, Prechl Jozsef and Tchorbanov Andrey, Humanized SCID Mice Models of SLE, Current Pharmaceutical Design 2011; 17 (13) . https://dx.doi.org/10.2174/138161211795703780
DOI https://dx.doi.org/10.2174/138161211795703780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Release of Growth Factors, Cytokines and Therapeutic Molecules by Hyaluronan-based Hydrogels
Current Pharmaceutical Biotechnology Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease
Current Neuropharmacology B Cells: Programmers of CD4 T Cell Responses
Infectious Disorders - Drug Targets Large-Scale Prediction of Drug Targets Based on Local and Global Consistency of Chemical-Chemical Networks
Combinatorial Chemistry & High Throughput Screening Immune Response Towards Snake Venoms
Inflammation & Allergy - Drug Targets (Discontinued) The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects
Current Gene Therapy Endothelin-1 and Human Platelets
Current Vascular Pharmacology Soft Condensed Matter in Pharmaceutical Design
Current Pharmaceutical Design Exploring the Potential of IL-1β Inhibitor Diacerein and its Combination with 5-aminosalicylic Acid for the Possible Ameliorating Effect in TNBSinduced Experimental Colitis in Wistar Rats
Current Drug Therapy Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials The Relevance of Peripheral Immune Tolerance in Normal Pregnancy and its Potential Failure in Gestation-Associated Diseases
Current Women`s Health Reviews Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Carbohydrate-Dependent Defense Mechanisms Against Helicobacter pylori Infection
Current Drug Metabolism Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews